B
Bart N.M. van Berckel
Researcher at VU University Amsterdam
Publications - 336
Citations - 12883
Bart N.M. van Berckel is an academic researcher from VU University Amsterdam. The author has contributed to research in topics: Dementia & Medicine. The author has an hindex of 57, co-authored 282 publications receiving 10176 citations. Previous affiliations of Bart N.M. van Berckel include VU University Medical Center & Utrecht University.
Papers
More filters
Journal ArticleDOI
Steps towards the implementation of amyloid‐PET in memory clinics: AMYPAD Diagnostic and Patient Management Study
Daniele Altomare,Ingrid S. van Maurik,Camilla Caprioglio,Frederik Barkhof,Lyduine E. Collij,Philip Scheltens,Bart N.M. van Berckel,Isadora Lopes Alves,Valentina Garibotto,Christian Moro,Julien Delrieu,José Luis Molinuevo,Oriol Grau-Rivera,Juan Domingo Gispert,Alexander Drzezga,Frank Jessen,Agneta Nordberg,Zuzana Walker,Jean-François Démonet,R. Gismondi,Gill Farrar,Andrew W. Stephens,Johannes Berkhof,Giovanni B. Frisoni +23 more
TL;DR: In most countries, amyloid PET is not routinely used in clinical practice as discussed by the authors , and the choice of whether to pay for it depends on its cost-effectiveness and on the safety of the procedure of disclosure.
Journal ArticleDOI
Mechanisms linking hearing loss with risk for dementia depends on age
Jochum J. van 't Hooft,Wiesje Pelkmans,Jori Tomassen,Cas Smits,Nienke Legdeur,Anouk den Braber,Frederik Barkhof,Bart N.M. van Berckel,Maqsood Yaqub,Philip Scheltens,Yolande A.L. Pijnenburg,Pieter Jelle Visser,Betty M. Tijms +12 more
TL;DR: In this article , age-related hearing loss has been associated with increased prevalence and incidence of dementia, but the underlying mechanisms that connect hearing loss with dementia remain largely unclear, while the link between hearing loss and dementia remains largely unclear.
Journal ArticleDOI
FDA approval of lecanemab: the real start of widespread amyloid PET use? — the EANM Neuroimaging Committee perspective
Journal ArticleDOI
Neurobiological basis and risk factors of persistent fatigue and concentration problems after COVID-19: study protocol for a prospective case–control study (VeCosCO)
A. Verveen,Sander C.J. Verfaillie,Denise Visser,Emma M. Coomans,Brent Appelman,Frederik Barkhof,Ronald Boellaard,Godelieve J. de Bree,Elsmarieke van de Giessen,Sandeep S.V. Golla,Caroline M. van Heugten,Janneke Horn,Hanneke E. Hulst,Menno D. de Jong,T. A. Kuut,Tessa van der Maaden,Yvonne M G van Os,Maria Prins,Arjen J. C. Slooter,Johanna M A Visser-Meily,Michèle van Vugt,Cees C. van den Wijngaard,Pythia T. Nieuwkerk,Hans Knoop,Nelleke Tolboom,Bart N.M. van Berckel +25 more
TL;DR: In this paper , the authors investigate the relation between persistent fatigue and neuropsychological functioning and determine risk factors and at-risk phenotypes for the development of persistent fatigue, including the presence of postexertional malaise and describe consequences of persistent complaints on quality of life, healthcare consumption and physical functioning.
Journal ArticleDOI
Differential responsiveness of outcome measures according to biomarker inclusion criteria: implications for trial design
Lois Ottenhoff,Everard G. B. Vijverberg,Niels D. Prins,Lior A. Kroeze,Argonde C. van Harten,Bart N.M. van Berckel,Wiesje M. van der Flier,Sietske A.M. Sikkes,Heleen M.A. Hendriksen +8 more
TL;DR: In this paper , the authors aimed to determine sensitivity to change over time, of commonly used cognitive measures, such as the earliest cognitive changes, in secondary prevention trials in preclinical Alzheimer's disease.